Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Hilton Head Island Packet, newsquawk.com, WTVB and Seeking Alpha. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 40m ago.
Quick answers
Why is "Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patie" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round Yahoo Finance · 6h ago
- Novo says its next-gen obesity drug tops Lilly rival in late-stage study Hilton Head Island Packet · 6h ago
- Novo Nordisk (NOVOB DC) announces topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, with CagriSema proving superior to tirzepatide and weight loss of 21% newsquawk.com · 6h ago
- Novo says CagriSema tops Lilly rival in diabetes patients for weight loss WTVB · 6h ago
- Novo Nordisk says CagriSema bests Eli Lilly's Zepbound (NVO:NYSE) Seeking Alpha · 6h ago
- Novo’s CagriSema delivers superior weight loss versus tirzepatide PharmaLive · 6h ago
- Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients Reuters · 6h ago
Topics
Related trends
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Wegovy maker Novo shares slump as management grilled on pricing, M&A
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Why Novo Stock Is Dropping After Drugmaker Unveils Ambitious Growth Plan
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Novo Nordisk shares slide despite aggressive obesity targets as investors demand a broader long-term strategy.
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.